Novartis and the European Migraine and Headache Alliance (EMHA) announced initial findings from the largest global migraine patient study to date, involving over 11,000 people from 31 countries.
“In this case, less is more. We’re now able to spare many patients with colon cancer unnecessary side effects of an additional 3 months of chemotherapy without compromising results.